Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner CP, White D, Chu MP, Jimenez-Zepada VH, Song K, Mccurdy A, Mian H, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Kaedbey R, Louzada M, LeBlanc R. Tanguay M, et al. Among authors: mccurdy a. Cancer Med. 2024 Nov;13(21):e70332. doi: 10.1002/cam4.70332. Cancer Med. 2024. PMID: 39499045 Free PMC article.
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, Sebag M, Song K, White D, Stakiw J, LeBlanc R, Reiman A, Aslam M, Louzada M, Kotb R, Gul E, Atenafu E, Venner CP. Cherniawsky HM, et al. Among authors: mccurdy a. Haematologica. 2021 Jun 1;106(6):1733-1736. doi: 10.3324/haematol.2020.259093. Haematologica. 2021. PMID: 33054120 Free PMC article. No abstract available.
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, Sebag M, Song K, White D, Stakiw J, LeBlanc R, Reiman A, Louzada M, Aslam M, Kotb R, Gul E, Atenafu E, Venner CP. Cherniawsky HM, et al. Among authors: mccurdy a. Eur J Haematol. 2021 May;106(5):673-681. doi: 10.1111/ejh.13596. Epub 2021 Feb 16. Eur J Haematol. 2021. PMID: 33539037
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Jimenez-Zepeda VH, Venner C, McCurdy A, Masih-Khan E, Atenafu EG, Sebag M, Stakiw J, Song K, LeBlanc R, Reiman T, Louzada M, Kotb R, Gul E, Reece D. Jimenez-Zepeda VH, et al. Among authors: mccurdy a. Br J Haematol. 2021 May;193(3):532-541. doi: 10.1111/bjh.17350. Epub 2021 Feb 9. Br J Haematol. 2021. PMID: 33559897 Clinical Trial.
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A, Venner CP, Masih-Khan E, Louzada M, LeBlanc R, Sebag M, Song K, Jimenez-Zepeda VH, Kotb R, Kardjadj M, Mian H, White D, Stakiw J, Aslam M, Reiman A, Gul E, Reece D. McCurdy A, et al. Curr Oncol. 2022 Mar 2;29(3):1575-1582. doi: 10.3390/curroncol29030132. Curr Oncol. 2022. PMID: 35323332 Free PMC article.
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
Mian H, Reece D, Masih-Khan E, McCurdy A, Kardjadj M, Jimenez-Zepeda VH, Song K, Louzada M, LeBlanc R, Sebag M, White D, Stakiw J, Reiman A, Kotb R, Aslam M, Gul E, Venner CP. Mian H, et al. Among authors: mccurdy a. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):608-617. doi: 10.1016/j.clml.2022.03.002. Epub 2022 Mar 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35379589
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
LeBlanc R, Mian H, Reece D, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, McCurdy A, Song K, Sebag M, Louzada M, White D, Stakiw J, Kotb R, Reiman A, Aslam M, Gul E, Venner CP. LeBlanc R, et al. Among authors: mccurdy a. Br J Haematol. 2022 Jul;198(1):93-102. doi: 10.1111/bjh.18172. Epub 2022 Apr 5. Br J Haematol. 2022. PMID: 35383886
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
Mian H, LeBlanc R, Louzada M, Masih-Khan E, McCurdy A, Venner CP, Stakiw J, Kardjadj M, Jimenez-Zepeda VH, Sebag M, White D, Aslam M, Song K, Reiman A, Kotb R, Gul E, Reece D. Mian H, et al. Among authors: mccurdy a. Cancer Med. 2023 Feb;12(4):4357-4362. doi: 10.1002/cam4.5245. Epub 2022 Sep 26. Cancer Med. 2023. PMID: 36161712 Free PMC article.
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A, Louzada M, Venner CP, Visram A, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, LeBlanc R, Sebag M, Song K, White D, Mian H, Stakiw J, Reiman A, Aslam M, Kotb R, Gul E, Reece D. McCurdy A, et al. EJHaem. 2022 Aug 31;3(4):1252-1261. doi: 10.1002/jha2.559. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467802 Free PMC article.
128 results